Showing results (41-50 of 60) with videos related to

Sort By:
Pageof 6
British Journal of Haematology|May 4, 2021
Comparison of immunohistochemistry and gene expression profiling subtyping for diffuse large B-cell lymphoma in the phase III clinical trial of R-CHOP ± ibrutinibSriram Balasubramanian, Songbai Wang, Christopher Major, et al.
Clinical and Translational Science|June 26, 2020
Early M-Protein Dynamics Predicts Progression-Free Survival in Patients With Relapsed/Refractory Multiple MyelomaXiaoyu Yan, Xu Steven Xu, Katja C Weisel, et al.
The Journal of Investigative Dermatology|October 6, 2022
Expression Patterns of microRNAs and Associated Target Genes in Ulcerated Primary Cutaneous MelanomaMallory J DiVincenzo, Emily Schwarz, Casey Ren, et al.
The Oncologist|March 13, 2020
Challenges and Opportunities to Updating Prescribing Information for Longstanding Oncology DrugsErin P Balogh, Andrew B Bindman, S Gail Eckhardt, et al.
Ejhaem|December 5, 2022
Ibrutinib and rituximab plus cyclophosphamide, doxorubicin, vincristine and prednisone in patients with previously untreated non-germinal centre B-cell-like diffuse large B-cell lymphoma: A Chinese subgroup analysis of the phase III PHOENIX trialJun Zhu, Xiaonan Hong, Yu Qin Song, et al.
Leukemia|August 13, 2022
Molecular determinants of outcomes in relapsed or refractory mantle cell lymphoma treated with ibrutinib or temsirolimus in the MCL3001 (RAY) trialCiara L Freeman, Prasath Pararajalingam, Ling Jin, et al.
Genes & Diseases|April 4, 2023
Inhibition of PRMT5 by market drugs as a novel cancer therapeutic avenueLakshmi Prabhu, Matthew Martin, Lan Chen, et al.
Clinical Lymphoma, Myeloma & Leukemia|June 10, 2021
Daratumumab, Bortezomib, and Dexamethasone Versus Bortezomib and Dexamethasone in Chinese Patients with Relapsed or Refractory Multiple Myeloma: Phase 3 LEPUS (MMY3009) StudyJin Lu, Weijun Fu, Wei Li, et al.
Blood Advances|December 21, 2022
Ibrutinib plus RICE or RVICI for relapsed/refractory mature B-cell non-Hodgkin lymphoma in children and young adults: SPARKLE trialG A Amos Burke, Luciana Vinti, Edita Kabickova, et al.
Plos Genetics|May 3, 2013
Breakpoint analysis of transcriptional and genomic profiles uncovers novel gene fusions spanning multiple human cancer typesCraig P Giacomini, Steven Sun, Sushama Varma, et al.
Pageof 6